Condition: Non Small Cell Lung Cancer · Stage IIIB Non-small Cell Lung Cancer · Stage IIIC Non-Small Cell Lung Cancer · Sponsor: Gene Solutions
This is an observational study, aiming to investigate whether the ctDNA dynamics analyzed by the K-TrackTM assay could predict early response to Tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC). 1. Determine relationship between ctDNA dynamics and clinical response to TKI, * No response/progressive disease = ctDNA levels increase from baseline * Partial response/stable disease = ctDNA levels decrease from baseline * Complete response = ctDNA clearance. 2. Compare and combine ctDNA dynamics and RECIST1.1 to predict clinical response. 3. Determine relationship between ctDNA dynamics and progression free survival, overall survival.
This description comes directly from the study's public registry record.
Lan NL Tu, PhD · +84888843489 · lantu@genesolutions.vn
VAN T Phan, MSc · +84908145990 · vanphan@genesolutions.vn
Always discuss trial participation with your own doctor first.
| Medical Genetics Institute | Ho Chi Minh City, Vietnam | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06167460